Cargando…
User preference for a portable syringe pump for iloprost infusion
PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447001/ https://www.ncbi.nlm.nih.gov/pubmed/26056502 http://dx.doi.org/10.2147/PROM.S81473 |
_version_ | 1782373532733276160 |
---|---|
author | Laria, Antonella Lurati, Alfredo Maria Re, Katia Angela Marrazza, Maria Grazia Mazzocchi, Daniela Farina, Alberto Scarpellini, Magda |
author_facet | Laria, Antonella Lurati, Alfredo Maria Re, Katia Angela Marrazza, Maria Grazia Mazzocchi, Daniela Farina, Alberto Scarpellini, Magda |
author_sort | Laria, Antonella |
collection | PubMed |
description | PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde(®), Italfarmaco S.p.A., Milan, Italy) at the Department of Rheumatology, Magenta Hospital, Milan, Italy. PATIENTS AND METHODS: Thirty-four consecutive SSc patients receiving stable therapy with iloprost, previously administered with a fixed pump, were treated using the portable Infonde(®) pump. Patients (n=34) and nurses (n=4) were asked to answer a nine- and six-item questionnaire, respectively, to assess the satisfaction of the administration comparing the new device versus the previous one. The health care staff of the ward developed the questionnaire, and the response scores ranged from 0 (fixed device better) to 10 (portable device better); thus a score >5 indicates a preference for Infonde(®). RESULTS: Patients’ answers indicated a preference towards the new portable syringe pump, versus the previous fixed pump. Questionnaires administered to patients generated a total of 306 responses, with over 95% of the responses in the range 8–10, of which 89% had a score equal to 10. The responses of nurses showed a score equal to 10 in 100% cases. No significant adverse events were recorded, indicating no change in the tolerability profile of the drug. CONCLUSION: Iloprost administration with Infonde(®) pump was preferred by both patients and health care professionals, and was well tolerated. The possibility to perform daily activities and the freedom of movement suggest a positive impact of Infonde(®) on the treatment, with a potential favorable effect on the quality of life of patients during the many hours spent receiving the infusion. |
format | Online Article Text |
id | pubmed-4447001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44470012015-06-08 User preference for a portable syringe pump for iloprost infusion Laria, Antonella Lurati, Alfredo Maria Re, Katia Angela Marrazza, Maria Grazia Mazzocchi, Daniela Farina, Alberto Scarpellini, Magda Patient Relat Outcome Meas Original Research PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde(®), Italfarmaco S.p.A., Milan, Italy) at the Department of Rheumatology, Magenta Hospital, Milan, Italy. PATIENTS AND METHODS: Thirty-four consecutive SSc patients receiving stable therapy with iloprost, previously administered with a fixed pump, were treated using the portable Infonde(®) pump. Patients (n=34) and nurses (n=4) were asked to answer a nine- and six-item questionnaire, respectively, to assess the satisfaction of the administration comparing the new device versus the previous one. The health care staff of the ward developed the questionnaire, and the response scores ranged from 0 (fixed device better) to 10 (portable device better); thus a score >5 indicates a preference for Infonde(®). RESULTS: Patients’ answers indicated a preference towards the new portable syringe pump, versus the previous fixed pump. Questionnaires administered to patients generated a total of 306 responses, with over 95% of the responses in the range 8–10, of which 89% had a score equal to 10. The responses of nurses showed a score equal to 10 in 100% cases. No significant adverse events were recorded, indicating no change in the tolerability profile of the drug. CONCLUSION: Iloprost administration with Infonde(®) pump was preferred by both patients and health care professionals, and was well tolerated. The possibility to perform daily activities and the freedom of movement suggest a positive impact of Infonde(®) on the treatment, with a potential favorable effect on the quality of life of patients during the many hours spent receiving the infusion. Dove Medical Press 2015-05-19 /pmc/articles/PMC4447001/ /pubmed/26056502 http://dx.doi.org/10.2147/PROM.S81473 Text en © 2015 Laria et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Laria, Antonella Lurati, Alfredo Maria Re, Katia Angela Marrazza, Maria Grazia Mazzocchi, Daniela Farina, Alberto Scarpellini, Magda User preference for a portable syringe pump for iloprost infusion |
title | User preference for a portable syringe pump for iloprost infusion |
title_full | User preference for a portable syringe pump for iloprost infusion |
title_fullStr | User preference for a portable syringe pump for iloprost infusion |
title_full_unstemmed | User preference for a portable syringe pump for iloprost infusion |
title_short | User preference for a portable syringe pump for iloprost infusion |
title_sort | user preference for a portable syringe pump for iloprost infusion |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447001/ https://www.ncbi.nlm.nih.gov/pubmed/26056502 http://dx.doi.org/10.2147/PROM.S81473 |
work_keys_str_mv | AT lariaantonella userpreferenceforaportablesyringepumpforiloprostinfusion AT luratialfredomaria userpreferenceforaportablesyringepumpforiloprostinfusion AT rekatiaangela userpreferenceforaportablesyringepumpforiloprostinfusion AT marrazzamariagrazia userpreferenceforaportablesyringepumpforiloprostinfusion AT mazzocchidaniela userpreferenceforaportablesyringepumpforiloprostinfusion AT farinaalberto userpreferenceforaportablesyringepumpforiloprostinfusion AT scarpellinimagda userpreferenceforaportablesyringepumpforiloprostinfusion |